Abstract
In-stent restenosis (ISR) caused by neointimal hyperplasia is the major drawback after percutaneous coronary intervention (PCI) for obstructive coronary disease, occurring in up to 40% of lesions. Recently, one of the most intriguing new therapies developed is drug-eluting stents (DES) that target the central phenomenon of cellular proliferation that causes ISR. The benefits of stent-based drug delivery include maximizing the local tissue levels of therapeutic agents while minimizing systemic toxicity. Numerous DES using different thin-film polymeric drug carrier have been developed and tested, those eluting either antimitotic or antimicrotublar agents such as sirolimus and paclitaxel have been shown effective in clinical trials. Two DES, the J Cypher (sirolimus-eluting) and the Boston Scientific Taxus (paclitaxel-eluting) stents, are commercially available in the U.S. after a number of randomized trials demonstrated reductions in late lumen loss, binary restenosis rate, and need for repeat revascularization compared with bare-metal stents (BMS). Because ISR is multifactorial, ideal agents for DES should inhibit thrombus formation, inflammation and cellular proliferation as well as enhance re-endothelialization. The next generation of DES currently undergoing preclinical studies includes new technology, new stent designs and materials, biological polymers, bioabsorbable stents coated with new drugs including stent based gene, as well as cell delivery. The current paper will review and discuss the current and future status of DES.
Keywords: Drug eluting stents, In-stent restenosis, Stent thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Drug-Eluting Stents: Present and Future
Volume: 6 Issue: 2
Author(s): Lakshmana Pendyala, Refat Jabara, Toshiro Shinke, Nicolas Chronos, Keith Robinson, Jinsheng Li and Dongming Hou
Affiliation:
Keywords: Drug eluting stents, In-stent restenosis, Stent thrombosis
Abstract: In-stent restenosis (ISR) caused by neointimal hyperplasia is the major drawback after percutaneous coronary intervention (PCI) for obstructive coronary disease, occurring in up to 40% of lesions. Recently, one of the most intriguing new therapies developed is drug-eluting stents (DES) that target the central phenomenon of cellular proliferation that causes ISR. The benefits of stent-based drug delivery include maximizing the local tissue levels of therapeutic agents while minimizing systemic toxicity. Numerous DES using different thin-film polymeric drug carrier have been developed and tested, those eluting either antimitotic or antimicrotublar agents such as sirolimus and paclitaxel have been shown effective in clinical trials. Two DES, the J Cypher (sirolimus-eluting) and the Boston Scientific Taxus (paclitaxel-eluting) stents, are commercially available in the U.S. after a number of randomized trials demonstrated reductions in late lumen loss, binary restenosis rate, and need for repeat revascularization compared with bare-metal stents (BMS). Because ISR is multifactorial, ideal agents for DES should inhibit thrombus formation, inflammation and cellular proliferation as well as enhance re-endothelialization. The next generation of DES currently undergoing preclinical studies includes new technology, new stent designs and materials, biological polymers, bioabsorbable stents coated with new drugs including stent based gene, as well as cell delivery. The current paper will review and discuss the current and future status of DES.
Export Options
About this article
Cite this article as:
Pendyala Lakshmana, Jabara Refat, Shinke Toshiro, Chronos Nicolas, Robinson Keith, Li Jinsheng and Hou Dongming, Drug-Eluting Stents: Present and Future, Cardiovascular & Hematological Agents in Medicinal Chemistry 2008; 6 (2) . https://dx.doi.org/10.2174/187152508783955051
DOI https://dx.doi.org/10.2174/187152508783955051 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Update on the Pathophysiological Role of Intracellular Signaling Pathways in Atherosclerotic Plaques and Ischemic Myocardium
Current Signal Transduction Therapy Drug Eluting Stents and Beyond
Current Pharmaceutical Design Normal Bicaudate Index by Aging
Current Medical Imaging Efficient Vessel Segmentation Based on Proposed Adaptive Conditional Random Field Model
Recent Advances in Computer Science and Communications Mechanical Thrombectomy in Acute Ischaemic Stroke: A Review of the Literature, Clinical Effectiveness and Future Use
CNS & Neurological Disorders - Drug Targets Injectable <i>In-Situ</i> Forming Depot of Doxycycline Hyclate/α-Cyclodextrin Complex Using PLGA for Periodontitis Treatment: Preparation, Characterization, and <i>In-Vitro</i> Evaluation
Current Drug Delivery Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design Sirolimus Eluting Stent: A New Era in Interventional Cardiology?
Current Pharmaceutical Design Application of Transcranial Color-Coded Duplex Sonography in Stroke Diagnosis
Current Medical Imaging 18F-fluoro-deoxy-D-glucose PET/CT in Establishing the Relationship Between the Metabolic Activity of Aorta and Iliac Artery Aneurysms in Cancer Patients
Current Medical Imaging Marfan Syndrome and Related Heritable Thoracic Aortic Aneurysms and Dissections
Current Pharmaceutical Design Editorial [(Hot Topic Novel Drug Therapies in the Treatment of SAH) Guest Editors: Surya Karri and Christopher S. Ogilvy]
Current Drug Safety The Effect of Anti-B-cell Therapy on the Development of Atherosclerosis in Patients with Rheumatoid Arthritis
Current Pharmaceutical Design Complex Inheritance for Susceptibility to Sudden Cardiac Death
Current Pharmaceutical Design Cerebrovascular Ultrasonography for Selecting Patients for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Stenting Renal Artery Stenosis: What is the Fuss All About?
Reviews on Recent Clinical Trials Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Three-Dimensional Intravenous Digital Subtraction Angiography Using Flat Panel Detector System in Vascular Mapping of the External Carotid Artery: A Comparison with 3-Dimensional Computed Tomography Angiography
Current Medical Imaging Oxidative Stress: Meeting Multiple Targets in Pathogenesis of Vascular Endothelial Dysfunction
Current Drug Targets